Professor, Medicine, University of Maryland School of Medicine
Oncology
Dr. Ashraf Z. Badros, MD
|
|
Give Review
Ashraf Z. Badros practices Oncology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Ashraf Z. Badros has written publications. He has 24 publications published with PubMed. The lastest paper is: 'Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.' Ashraf Z. Badros accepts Medicare payments and is registered with Medicare.gov.
Publications
- Central Nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Result...
- Major clinical response to nivolumab in relapsed/refractory Hodgkin Lymphoma after allogeneic stem cell transplantation.
- A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.
- NY-ESO-1-specific TCR-engineered T Cells mediate sustained antigen-specific antitumor effects in myeloma.
- Disparities in black and white patients with multiple Myeloma referred for autologous hematopoietic transplantation: A single center study.
- Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple M...
- A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma.
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autolo...
- Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem Cell transplantation (SCT) in patie...
- The role of clonal evolution in smoldering multiple Myeloma.
- Carfilzomib in multiple Myeloma patients with renal impairment: pharmacokinetics and safety.
- Plasma cell Leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
- Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic Leukemia and multiple myeloma.
- In the age of novel therapies, what defines high-risk multiple Myeloma?
- Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and Anemia.
- The role of maintenance therapy in the treatment of multiple Myeloma.
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple Myeloma.
- Natural history of osteonecrosis of the jaw in patients with multiple Myeloma.
- Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple Myeloma patients.
- Case 38-2004: a large tumor of the skull.
- Hypothyroidism in patients with multiple Myeloma following treatment with thalidomide.
- Racial differences in primary cytogenetic abnormalities in multiple Myeloma: a multi-center study.
Schools
Ain Shams University Faculty Of Medicine
Georgetown University Hospital
Harbor Hospital Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Georgetown University Hospital -
Ain Shams University Faculty of Medicine
Hospital
-
University of Maryland Baltimore Washington Medical Center -
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1821038241 | |
| NPPES Provider LastName | BADROS | |
| NPPES Provider FirstName | ASHRAF | |
| NPPES Provider ZIPCode | 212630001 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 361.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 20.0 | |
| Percent Opioid Claims | 5.54 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1821038241 |
| Last Name Of The Provider | BADROS |
| First Name Of The Provider | ASHRAF |
| View All |
Similar Doctors
|
|
Dr. Hayden G. Braine, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Richard F. Ambinder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Curt I. Civin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mya S. Thein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jian L. Campian, MD |